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Abstract
Background In utero exposure to obesity is consistently associated with increased risk of metabolic disease, obesity and
cardiovascular dysfunction in later life despite the divergence of birth weight outcomes. The placenta plays a critical role in
offspring development and long-term health, as it mediates the crosstalk between the maternal and fetal environments.
However, its phenotypic and molecular modifications in the context of maternal obesity associated with fetal growth
restriction (FGR) remain poorly understood.
Methods Using a mouse model of maternal diet-induced obesity, we investigated changes in the placental transcriptome
through RNA sequencing (RNA-seq) and Ingenuity Pathway Analysis (IPA) at embryonic day (E) 19. The most differ-
entially expressed genes (FDR < 0.05) were validated by Quantitative real-time PCR (qPCR) in male and female placentae at
E19. The expression of these targets and related genes was also determined by qPCR at E13 to examine whether the
observed alterations had an earlier onset at mid-gestation. Structural analyses were performed using immunofluorescent
staining against Ki67 and CD31 to investigate phenotypic outcomes at both timepoints.
Results RNA-seq and IPA analyses revealed differential expression of transcripts and pathway interactions related to
placental vascular development and tissue morphology in obese placentae at term, including downregulation of Muc15,
Cnn1, and Acta2. Pdgfb, which is implicated in labyrinthine layer development, was downregulated in obese placentae at
E13. This was consistent with the morphological evidence of reduced labyrinth zone (LZ) size, as well as lower fetal weight
at both timepoints irrespective of offspring sex.
Conclusions Maternal obesity results in abnormal placental LZ development and impaired vascularization, which may
mediate the observed FGR through reduced transfer of nutrients across the placenta.
Introduction
The prevalence of obesity has nearly tripled since 1975 [1].
As a consequence, the number of women who are classified
as overweight or obese during pregnancy has risen sub-
stantially, estimated at 38.9 million in 2014 [2]. This is
especially concerning as offspring born to obese mothers
are more likely to have poor neonatal outcomes [3] and to
These authors contributed equally: Daniela de Barros Mucci, Laura C.
Kusinski
* Daniela de Barros Mucci
danimucci@gmail.com
* Laura C. Kusinski
lck34@medschl.cam.ac.uk
1 Metabolic Research Laboratories and MRC Metabolic Diseases
Unit, Wellcome Trust-MRC Institute of Metabolic Science,
University of Cambridge, Cambridge, UK
2 Nutritional Biochemistry Laboratory, Institute of Nutrition Josué
de Castro, Federal University of Rio de Janeiro, Rio de Janeiro,
Brazil
3 Nutritional Epidemiology Observatory, Institute of Nutrition Josué
de Castro, Federal University of Rio de Janeiro, Rio de Janeiro,
Brazil
Supplementary information The online version of this article (https://
doi.org/10.1038/s41366-020-0561-3) contains supplementary















develop obesity, insulin resistance, hypertension and dys-
lipidemia later in life [4]. Interestingly, maternal obesity
leads to divergent birth weight outcomes; while it is often
shown to increase the risk of macrosomia [5, 6], a higher
incidence of low birth weight is also documented [6–8].
Although both are similarly associated with metabolic dis-
ease in later life, distinct placental alterations seem to
mediate these contrasting offspring phenotypes [9].
Changes in placental function are thought to be pivotal in
the development of pregnancy complications [10, 11] and
could also be a key link between the maternal and intrau-
terine milieu and long-term health of the offspring [12, 13].
Alterations in placental function and structure in response
to obesity and their underlying molecular mechanisms
have been explored both in humans and in animal models
[9, 14–17]. Yet, even though fetal growth restriction (FGR)
is recognized as a placenta-related disorder [18], the impact
of maternal obesity on the placental transcriptome in this
context remains largely unknown.
It has been shown that placentae from high fat diet-fed
obese mouse dams exhibit altered expression of epigenetic
machinery genes at term, which could alter the placental
epigenome and lead to FGR [19]. High fat diet-induced
obesity has also been found to alter the transcriptome of
placenta progenitor cells at early stages of development and
is associated with later changes in placental function
resulting in FGR [17]. In our mouse model of maternal diet-
induced obesity, in which dams are fed a hypercaloric
Western-like diet, we have shown that maternal hyper-
insulinemia is strongly associated with offspring insulin
resistance and excess placental lipid deposition and hypoxia
[20]. However, a clear understanding of the molecular
mechanisms behind these findings is still lacking and war-
rants further investigation.
It is recognized that the impact of stressors on placental
function and offspring health is closely linked to the stage
of tissue development, the type of insult and the sex of the
conceptus [21]. Thus, the aim of this study was to identify
global changes in the placental transcriptome and related
pathways in response to maternal obesity near term at
embryonic day (E) 19. Furthermore, we investigated whe-
ther the significant transcriptional alterations detected in
obese placentae were manifested earlier, i.e., in mid-
gestation (E13), and if these alterations translated into a
structural phenotype in male and female placentae.
Methods
Animals and diets
All experimental protocols were approved by the University
of Cambridge Animal Welfare and Ethical Review Board
and were carried under the Home Office Animals (Scientific
Procedures) Act 1986. The model has been described in
detail previously [20, 22]. Briefly, female C57BL/6J mice,
proven breeders, were randomly assigned either a standard
chow RM1 diet [7% simple sugars, 3% fat (wt/wt),
10.74 kJ/g] or an energy-rich highly palatable obesogenic
diet [10% simple sugars, 20% animal lard (wt/wt), 28.43 kJ/g]
supplemented with sweetened condensed milk [55% simple
sugar, 8% fat (wt/wt); Nestle, Croydon, UK], and fortified
with mineral and vitamin mix AIN93G. Both diets were fed
ad libitum and purchased from Special Dietary Services
(Witham, UK). Body composition was monitored (TD-
NMR, Bruker Minispec) and females were set up to breed if
body fat was between the thresholds of 10–12% or 35–40%
for Control and Obese dams, respectively. After mating for
the second time with RM1 fed males, dams were killed at
either E13 or E19 by rising CO2 concentration. Fetal and
placental weights were recorded. Placentae for molecular
analysis were immediately snap frozen on dry ice and stored
at −80 °C. For morphological assessment, samples were
fixed in 10% formalin for 48 h, stored in 70% ethanol and
then embedded in wax.
The sex of the fetuses at E19 was determined by visual
inspection of anogenital anatomy. At E13, DNA extracted
from tail tips was used for PCR sexing as described by
McFarlane et al. [23], using the SX primer pair. Amplicons
were loaded on 2% agarose gels and submitted to electro-
phoresis together with a 1 kb DNA ladder. Bands were
visualized with SYBR™ Safe DNA gel stain (Thermo
Fisher Scientific, Rochford, UK) under UV-illumination
and the genomic sex of each sample was determined
according to the number of bands and amplicon size.
RNA extraction
Placenta aliquots were homogenized in 700-µL Qiazol
using TissueRuptor (Qiagen, Manchester, UK). Total RNA
was isolated with miRNeasy Mini Kit (Qiagen) according to
the manufacturer’s instructions and including the optional
step of DNA digestion with RNase-Free DNAse Set (Qia-
gen). Extracted RNA was quantified by spectrophotometry
(Nanodrop™ Thermo Fisher Scientific) and stored at
−80 °C.
RNA sequencing and Ingenuity® Pathway Analysis
Total RNA was extracted from E19 male placentae (Control
n= 2 and Obese n= 3), as previously outlined. One
microgram of total RNA was depleted of ribosomal RNA
and PolyA tails of coding RNAs were captured by treatment
with Oligo-dT beads. Complementary DNA (cDNA)
libraries were generated after an amplification step,
according to the TruSeq Stranded Total RNA Sample
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Preparation Guide (Illumina, San Diego, CA, USA), and
quantified using KAPA Library Quantification Kit. Multi-
plex single-read sequencing was performed using Illumina
HiSeq 2500 (Illumina). Sequence reads were demultiplexed
using the CASAVA pipeline (Illumina) and then aligned to
the Mus musculus genome (GRCm38) using TopHat ver-
sion 2.0.11. Raw read counts and fragments per kilobase of
transcript per million mapped reads (FPKM) were generated
using Cufflinks version 2.2.1. A quality check of mapped
reads was executed using the R package CummeRbund.
Databases were trimmed for exclusion of very low detection
or undetectable genes. The resulting data were analyzed
using edgeR by calculating the likelihood ratio, and by
adjusting P values via Benjamini and Hochberg’s method to
control the false discovery rate (FDR). Ingenuity Pathway
Analysis (IPA) was applied to identify biological pathways
related to the genes that were differentially expressed
between Control and Obese E19 male placentae. The pla-
centa RNA sequencing (RNA-seq) data have been depos-
ited in GEO database under the accession number
GSE140013.
cDNA synthesis and Quantitative real-time PCR
(qPCR)
Total RNA was extracted from male and female placentae
of Control and Obese dams at E13 (n= 10/group from
separate litters) and E19 (n= 9/group from separate litters).
All samples used in the validations were different to those
used in the RNA-seq and therefore represent biological
replicates. Sample size was based on previous data sets/
power calculations. cDNA was generated from 1-μg RNA
using High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA). qPCR was
performed on QuantStudio 7 Flex Real-Time PCR System
(Applied Biosystems), using 200 nM specific primers
(Sigma-Aldrich, Gillingham, UK), 1× SYBR® Green
JumpStart™ Taq ReadyMix (Sigma-Aldrich) and cDNA
samples at a final dilution of 1:60. For primer sequences see
Supplementary Table S1. NormFinder software was used to
select the best combination of two out of four reference
genes [24]. qPCR results were normalized to the geometric
mean of the reference genes Gapdh and Sdha for E19
placentae, and Gapdh and Pmm1 for E13 placentae,
expression of which did not change between groups. Data
were expressed in arbitrary units relative to Male Control
average (2−ΔΔCq).
Structural analyses
E13 and E19 formalin-fixed placentae from males and
females were cut into 5-µm sections. Three serial sections
close to the midline of each placenta were selected for
staining. Antigen retrieval was performed with pH9 Target
Retrieval buffer [S2375 (Dako Agilent, Stockport, UK)] and
nonspecific binding sites were blocked with 3% goat serum.
Sections were incubated overnight at 4 °C with rabbit
polyclonal primary antibodies against Ki67 [1:200;
ab15580 (Abcam, Cambridge, UK)] or CD31 [1:500;
ab124432 (Abcam)].
Primary antibody binding was visualized by incubation
at room temperature for 1 h with a fluorescent-conjugated
goat polyclonal anti-rabbit IgG [1:1000; A11008 (Invitro-
gen, Warrington, UK)]. In negative control slides, placental
sections were incubated in 1.5% goat serum in TBS-T
instead of primary antibodies (Supplementary Fig. S1). All
sections were incubated with 1:2500 DAPI for 10 min at
room temperature to stain nuclei. Autofluorescence was
quenched by incubation with Vector TrueVIEW Auto-
fluorescence Quenching Kit [SP8400 (Vector Laboratories,
Peterborough, UK)].
Placental sections were imaged on an AxioScan Slide
Scanner (Zeiss, Cambridge, UK) and blindly analyzed using
HALO analysis software (Indica Labs, Corrales, NM,
USA). The DAPI channel image was used to define nuclear
outlines using the CytoNuclear FL module. For the analysis
of Ki67 staining (Supplementary Fig. S2), nuclear outlines
were transposed onto the 488-nm channel image and the
proportion of nuclei positive for Ki67 across the whole
section was recorded. Placental sections stained for the
endothelial cell marker CD31 were used to investigate
labyrinth zone (LZ) size and structure (Supplementary Fig.
S3). The border of the LZ was outlined manually at ×40
magnification (depicted in yellow) and total area was
recorded using HALO analysis software after canals were
excluded. The boundary with the junctional zone was
determined as the interface between the phenotypically
distinct spongiotrophoblast of the junctional zone and the
fetal capillaries of the LZ. The rest of the boundary was
either at the edge of the tissue image or at the interface with
the chorionic plate, which is structurally distinct from the
LZ, characterized by smaller nuclei and the absence of
CD31-positive endothelial cells. Indica Labs’ Tissue Clas-
sifier module was used to differentiate between fetal blood
vessels (lumen bound by CD31-positive endothelium) and
other tissue of the LZ.
Statistical analyses
Benjamini–Hochberg multiple testing correction [25] was
applied to the RNA-seq differential expression data and
only genes with FDR < 0.05 were considered significantly
different between the two experimental conditions. For
qPCR validation of RNA-seq differentially expressed
genes, comparisons were made between Control and Obese
placentae of the same sex, by Student’s t test.
Impact of maternal obesity on placental transcriptome and morphology associated with fetal growth. . . 1089
Anthropometric parameters and qPCR of selected targets
were analyzed by two-way analysis of variance (ANOVA)
followed by Tukey’s multiple comparisons test to estimate
the effects of maternal obesity and fetal sex at each
time point.
For the morphological analyses, the effects of gestational
age (E13 or E19), offspring sex (male or female), and
maternal diet (regular chow or obesogenic diet) on placental
phenotype were investigated by three-way ANOVA, and
backwards stepwise elimination was used to come to a
minimal model. Three-way ANOVA of the proportional
area of the LZ that was fetal capillaries data revealed no
significant effect of gestational age, maternal diet, or fetal
sex. However, there was a borderline significant interaction
between maternal diet and fetal sex (P= 0.055). In order to
identify if a maternal diet effect was only present in one sex,
these data were separated and sex-specific two-way ANO-
VAs (gestational age/maternal diet) were performed.
Only one sample from each litter was used for each
analysis, except in the case of offspring and placental
weights, in which each litter’s average was used as a single
data point. Data are presented as mean ± standard error of
the mean (SEM), and the threshold for significance was set
at P < 0.05, unless stated otherwise. Statistical analyses
were performed using R (R Core Team 2017) or Prism 6
(GraphPad Prism, La Jolla, CA, USA).
Results
Fetal and placental measurements
Fetal and placental weights were reduced in response to
obesity and female placentae were smaller than those of
males at both stages of gestation. There was no significant
difference in the ratio of fetal to placental weight, although
there was a trend (P= 0.05) toward higher placental effi-
ciency in females at E19 (Table 1).
RNA-seq, Ingenuity® Pathway Analysis and qPCR at
term placentae
The RNA-seq at E19 detected a total of 350 transcripts
differentially expressed in placentae of Obese compared
to Control males considering a significance threshold of
P < 0.05 (Fig. 1a, Supplementary Table S2). However, only
nine genes remained significantly altered after correction for
multiple testing (FDR < 0.05) (Fig. 1a, b). Ingenuity®
Pathway Analysis (IPA) was used with a less stringent
threshold (P < 0.05) to identify global changes in pathways
and biological functions promoted by maternal obesity. The
most significant diseases and bio functions are shown in
Fig. 1c.
Genes identified as significantly changed in response to
obesity by RNA-seq (FDR < 0.05) were validated in a larger
number of samples, all from independent litters, by qPCR
(Fig. 2) and results were confirmed in eight out of the nine
genes in E19 male placentae (i.e., Pi15, Gabrd, Sez6l,
Nup210, Acta2, Rnf222, Muc15, and Cnn1). These genes
were also examined in female placentae, however, only
Pi15, Nup210, Acta2, Rnf222, and Muc15 were sig-
nificantly modulated by obesity (Fig. 2).
Placental gene expression at different gestational
ages
All nine genes found differentially expressed in obese
male placentae at E19 were then investigated in E13
Table 1 Fetal and placental
weights at E13 and E19.
Control Obese P value




Fetal weight (g) 0.17 ± 0.01 0.16 ± 0.00 0.15 ± 0.01 0.14 ± 0.01 0.003 0.187
Placental
weight (mg)
94.0 ± 2.2 88.9 ± 3.5 89.7 ± 2.1 78.7 ± 2.9 0.015 0.008
Fetal:placental ratio 1.84 ± 0.06 1.85 ± 0.06 1.66 ± 0.08 1.76 ± 0.08 0.079 0.452
E19
Fetal weight (g) 1.23 ± 0.03 1.17 ± 0.03 1.02 ± 0.03 1.03 ± 0.02 <0.0001 0.339
Placental
weight (mg)
93.8 ± 5.1 81.7 ± 5.3 82.8 ± 1.9 73.1 ± 2.7 0.039 0.021
Fetal:placental ratio 13.45 ± 0.76 14.77 ± 0.92 12.38 ± 0.37 14.28 ± 0.78 0.331 0.051
Values are mean ± SEM. P values < 0.05 indicated in bold show significant effect of maternal obesity and
sex differences in the studied parameters according to two-way ANOVA followed by Tukey’s multiple
comparisons test, using each litter’s average as a single data (Control Male n= 6 and 9, Control Female n=
6 and 9, Obese Male n= 7 and 7, Obese Female n= 7 and 6, respectively, at E13 and E19).
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placentae (Fig. 3a). Pi15, Nup210, and Sez6l were upre-
gulated by maternal obesity in both sexes at mid-gestion.
Gabrd mRNA levels, which were upregulated in Obese
male placentae at E19, was downregulated by maternal
obesity at E13. Muc15, Nup210, and Acta2 expression was
higher in females compared to males at E13. Rnf222 and
Cnn1 were not differentially expressed in either sex at
E13, however, their transcript levels were very low com-
pared to E19.
Since genes involved in spiral artery remodeling (Muc15
and Cnn1) and labyrinthine pericytes (Acta2) that were
found to be dysregulated in obese placentae at E19 were not
affected at E13, we additionally measured the expression of
candidate genes recognized as relevant for these processes
at mid-gestation. Both Hand1 and Pdgfb were down-
regulated by maternal obesity in both sexes, but no differ-
ences were observed in Prl2c2 (Fig. 3b).
Immunofluorescent staining of placental
morphology
Phenotypic analyses were also conducted by immuno-
fluorescent staining of targets within pathways identified by
IPA. The marker Ki67 was used to investigate cellular
growth and proliferation. Cellular movement, assembly, and
organization were assessed through analyses of LZ size and
fetal vasculature structure, using CD31 as a marker of fetal
endothelial cells.
Fig. 1 RNA-seq identification
of differentially expressed
genes between Control (C,
n= 2) and Obese (O, n= 3)
male mouse placentae at E19.
a Volcano plot representing all
detected transcripts, distributed
according to −log10 P value in
the y-axis and log2 fold change
in the x-axis, with
downregulated genes shifted to
the left (P < 0.05 in blue) and
upregulated genes shifted to the
right (P < 0.05 in red).
Significantly altered genes after
correction for multiple testing
(FDR < 0.05) are depicted with a
pink diamond. b Heatmap
representation of genes
significantly regulated by
maternal obesity using a cutoff
FDR < 0.05, with scaled Z-score
color key of normalized counts
showing expression levels
ranging from blue (lower) to red
(higher). Genes are sorted from
lowest to highest log2 fold
change value. c Top diseases
and bio functions from
Ingenuity® Pathway Analysis
(IPA) of the RNA-seq data with
a threshold of P < 0.05, showing
the most significant molecular
and cellular functions
dysregulated in the placenta by
maternal obesity, sorted by
P value.
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E19 placentae had fewer cells (P < 0.05, Fig. 4a–c) and
a lower proportion of proliferating cells across the whole
placenta (P < 0.01, Fig. 4d–h) compared to E13. These
parameters were not affected by offspring sex or maternal
diet.
The size of the LZ was significantly reduced in placentae
from obese dams (P < 0.01, Fig, 4i–m). There was a sig-
nificant increase in LZ size from mid-gestation to term
(P < 0.01, Fig. 4i). Labyrinthine vascular organization was
analyzed by the proportion of the total LZ area that was
fetal blood vessels. A reduced model considering males and
females separately by two-way ANOVA (gestational age/
maternal condition) detected a reduction in area bound by
fetal capillaries within the LZ in female placentae of obese
dams (P < 0.05, Fig. 4n–p). Representative images of male
placentae are shown in Supplementary Fig. S4.
Discussion
The RNA-seq analysis revealed a total of 350 transcripts
differentially expressed in Obese male placentae at term.
Among the top downregulated transcripts, Muc15, Cnn1
and Acta2 were of particular significance as these genes are
required for appropriate development of placental vascu-
lature and related to key pathways identified by IPA such as
cellular movement, assembly and organization. Previous
studies have shown that Muc15 suppresses the migration/
invasion of trophoblast like-cells in vitro, a process impli-
cated in blood vessel remodeling in the maternal–fetal
interface [26]. Cnn1 is largely expressed by smooth muscle
cells [27] which line the uterine blood vessels and are lost in
the normal remodeling of maternal spiral arteries during
placental development [28]. Acta2 is a marker of pericytes
which surround fetal endothelial cells during blood vessel
development in the mouse LZ [29].
These data together suggest that exposure to maternal
obesity affects the remodeling of maternal spiral arteries and
the development of fetal blood vessels within the LZ, both
of which are crucial for adequate nutrient and oxygen
transfer across the placenta [28] and possibly linked to the
uteroplacental hemodynamic alterations present in pre-
eclampsia and intrauterine growth restriction [30–32].
Obese women are two to three times more likely to develop
preeclampsia [33] and hypertensive obstetric complications
are generally associated with small-for-gestational age
neonates [34]. Here, we see significant growth restriction in
the fetus which may result from poor uteroplacental perfu-
sion in addition to placental hypoxia previously suggested
in this model [20].
Furthermore, the RNA-seq analysis identified several
genes that have not been functionally described in placental
tissue thus far, but are conserved in humans and rodents.
Pi15 encodes a peptidase inhibitor that may regulate
extracellular matrix modifications [35] and has been
implicated in vascular defects in rat aorta [36], though its
role in placental vascularization is unknown. Gabrd gene
encodes the delta subunit of gamma-aminobutyric acid type
A receptor (GABAA). GABAA activation impacts stromal
cell proliferation and apoptosis during decidualization [37]
and increased expression of its pi subunit (GABRP) has
been detected in preeclamptic placentae [38]. NUP210 is a
Fig. 2 Validation of RNA-seq data by qPCR in E19 male and
female placentae. qPCR results were normalized to the reference
genes Gapdh and Sdha and are expressed as mean ± SEM in arbitrary
units relative to Male Controls. *P < 0.05, determined by Student’s
t test comparing qPCR data of same sex Control vs Obese, n= 9/
group.
Fig. 3 qPCR expression in E13 male and female placentae.
a Validated RNA-seq genes. b Hand1, required for trophoblast giant
cell (TGC) differentiation; Prl2c2, a marker of spiral artery-associated
TGC and canal-associated TGC; Pdgfb, a growth factor that regulates
placental labyrinthine layer development. qPCR data were normalized
to the reference genes Gapdh and Pmm1. Results are shown as mean ±
SEM in arbitrary units relative to Male Control average expression.
*Denotes maternal obesity effect (P < 0.05) and # denotes sex differ-
ence (P < 0.05), according to two-way ANOVA, n= 10/group.
ªRnf222 and Cnn1 expression levels were low at E13 placentae, with
average Cq values above 31 and 29, respectively.
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major component of the nuclear pore complex and is
required for regulation of gene expression during differ-
entiation and cell fate determination, as demonstrated in
myoblasts and embryonic stem cells [39]. Although the
function of SEZ6L is not well understood, it has been
shown both in mice and in vitro that this protein is almost
exclusively processed by β-site APP cleaving enzyme
(BACE) [40]; BACE1 and BACE2 are abundantly expres-
sed in human placentae and are upregulated in pregnancies
complicated with preeclampsia [41]. Lastly, Rnf222 is also a
protein-coding gene; however, no functional description has
been found.
Although information on these genes in placentae is
currently limited, it must be noted that a large number of
placental genes and related phenotypes remain unchar-
acterized. Recent efforts to systematically identify the genes
required for normal embryogenesis are still unravelling
many previously underappreciated placental defects [42].
Thus, our findings might represent novel targets that could






























Fig. 4 Immunofluorescent staining of targets related to the top
three molecular and cellular functions shown in IPA. All analyses
were conducted in both male and female placentae of mothers fed
either regular chow (C, Control group) or obesogenic diet (Ob, Obese
group), at E13 and E19. a–c The total number of cells in the placenta
decreased between E13 (n= 20) and E19 (n= 19). d–h The propor-
tion of Ki67-positive cells across the whole placenta decreased
between E13 (n= 20) and E19 (n= 19). i–m The size of the labyrinth
zone increased between E13 and E19, and was reduced in response to
maternal obesity (C n= 10, Ob n= 9, at each time point). n–p The
proportion of fetal capillaries within the labyrinth zone was decreased
by maternal obesogenic diet in females (C n= 10, Ob n= 9). a, d, i, n
Results are shown as mean ± SEM. Gestational age differences are
denoted by *P < 0.05, **P < 0.001, or ***P < 0.0001, and maternal
obesity effect is indicated by #P < 0.001, according to three-way
ANOVA. §Denotes maternal obesity effect (P < 0.05), determined by
two-way ANOVA analysis of E13 and E19 female placentae only.
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and associated adverse outcomes in the offspring. More-
over, additional genes might have been identified if a larger
sample size was used in the RNA-seq analysis.
When comparing both timepoints, most transcripts
exhibited a different expression pattern, including Muc15,
Cnn1, and Acta2 which were not affected by obesity at E13.
This could be due to low functional relevance of these
transcripts at mid-pregnancy rather than absence of altera-
tions in related cellular processes, as illustrated by low
Cnn1 mRNA levels in our analysis at E13 compared to E19
(data not shown). In fact, the mouse placenta undergoes a
transcriptome transition from the “development phase” of
organogenesis to the “mature phase” at mid-pregnancy [43].
Thus, we next used the IPA data to identify genes which
were previously shown to be both highly expressed at mid-
pregnancy and pivotal to spiral artery remodeling and for-
mation of fetal blood vessels in the LZ. Hand1, which is
required for trophoblast giant cell (TGC) differentiation
[44], was downregulated in placentae of obese dams.
However, maternal obesity had no effect on the expression
of Prl2c2, a marker of TGC that line maternal blood canal
spaces and spiral arteries in the definitive placenta [45].
Considering the complexity of spiral artery remodeling and
the limited number of transcripts that were analyzed here, it
remains to be established whether the alterations occur only
later in development or if other mechanisms are involved.
On the other hand, the growth factor Pdgfb was down-
regulated in response to obesity at E13 and could be a
relevant link to other molecular and phenotypic observa-
tions in our model. It has been shown that Pdgfb-deficient
placentae exhibit defective labyrinthine development, with
alterations in fetal blood vessel structure and reduced
numbers of pericytes from mid-pregnancy until term,
leading to growth restriction in PDGFB −/− embryos [29].
Here, lower expression of the pericyte marker Acta2 was
detected by RNA-seq and confirmed by qPCR in obese
placentae at E19. In addition, defects in LZ morphology and
FGR were observed in response to maternal obesity at E13
and persisted until E19.
As shown by our immunofluorescence staining, male and
female placentae from Obese dams exhibited reduced LZ
area, which is the primary site of gas, nutrient and waste
exchange between the maternal and fetal circulations in the
mouse [28], and a decrease in the proportion of fetal blood
vessels within the LZ was also evident in females. This is
further corroborated by recent evidence of lower vascularity
in placentae of high fat diet-fed dams both at mid-
pregnancy and near term, which was associated with pla-
cental transcriptome alterations in early stages of develop-
ment and FGR [17]. In addition, it has been suggested that
defects in placental villi vasculature seen in obese human
pregnancies could be partly due to obesity-associated tissue
hypoxia [46], which is also consistent with our model [20].
Next, we used IPA to investigate the mechanism behind
this reduction in LZ area. Cellular growth and proliferation
were pointed out as the main molecular and cellular func-
tions affected by obesity. Surprisingly, however, maternal
obesity had no effect on the number of Ki67-positive cells
in the placenta. Abnormalities in placental size are often
associated with disruption of cellular growth and/or apop-
tosis [47–49]. Thus, it is possible that other mechanisms
such as cell death could explain our results, although lim-
itations to our analysis, which was not zone-specific, cannot
be discounted. In this regard, it has been shown in a mouse
model of high fat diet-induced obesity through phospho-
histone H3 staining that the proliferating cells in placenta
are mostly restricted to the labyrinthine layer and appear
reduced in response to obesity within this region [50].
Despite these morphological disturbances, changes in
tissue structure that are expected to occur from mid-
pregnancy until term seemed preserved in obese placentae.
The LZ is well-reported to expand as pregnancy progresses,
so that the transport capacity of the placenta can meet the
nutrient demands of the growing fetus [50–52]. Accord-
ingly, we found that labyrinth area increased between E13
and E19, irrespective of maternal diet.
We also observed significant differences in placentae
which are specific to fetal sex. Female placentae were
smaller than male counterparts at all timepoints and
maternal conditions, which is consistent with observations
from both human cohorts [53] and studies in mice [19, 54].
Moreover, we found sex differences in a subset of genes,
with females exhibiting slightly increased expression.
Similarly, global transcriptomic analysis in normal full-term
human placentae revealed higher overall mRNA levels in
females compared to males [55]. Sexual dimorphism in the
context of developmental programming is increasingly
commonly reported [56]. How these relate to sex-specific
responses of the placenta to a suboptimal environment
remain to be determined.
Overall, we have shown through genome-wide analysis
that maternal obesity induces a dysregulation of transcripts
and pathway interactions related to placental vasculature
and structure. FGR, as well as changes in placental mor-
phology and a gene expression signature associated with
impaired labyrinthine development, were detectable at mid-
pregnancy, suggesting an enduring negative effect of
maternal obesity over these processes. The LZ is the
exchange region of the murine placenta and reductions in its
size and vasculature may impair the transport of nutrients
from the maternal circulation to the developing fetus, thus
restricting its growth. Disruption of placental structure
could thus represent an important factor contributing to the
development of FGR in pregnancies complicated by
maternal obesity. Moreover, novel targets were revealed by
our RNA-seq analysis. Characterizing their functional roles
1094 D. de Barros Mucci et al.
in the placenta will help us better understand the processes
mediating the effects of maternal obesity on offspring out-
comes and potentially inform suitable interventions.
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